Hantz Financial Services Inc. Raises Stock Position in Novo Nordisk A/S (NYSE:NVO)

Hantz Financial Services Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,879 shares of the company’s stock after purchasing an additional 2,104 shares during the period. Hantz Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $15,903,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Natixis Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Versant Capital Management Inc purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $86,000. Talbot Financial LLC bought a new position in Novo Nordisk A/S in the fourth quarter worth $4,066,000. Finally, Zions Bancorporation N.A. lifted its position in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $85.00 on Wednesday. The company has a 50 day moving average of $94.75 and a 200 day moving average of $114.02. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The firm has a market cap of $381.45 billion, a P/E ratio of 27.51, a PEG ratio of 0.90 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NVO. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.